The next meeting of the Transparency Council will be held on Monday, February 10.
Agenda:
- Preparation of a position paper on the evaluation of the drug Skyclarys (omaveloxolonum) under the drug program: "Treatment of patients with Friedreich's ataxia" (ICD-10: G11.1).
- Preparation of an opinion on the assessment of the appropriateness of changes within the drug program B.71 "Treatment with interferon-free therapy for patients with chronic h...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at english@medexpress.pl.
If you already have an account, please log in
